<DOC>
	<DOCNO>NCT02729701</DOCNO>
	<brief_summary>The purpose study learn whether daily use Duavee速 accept tolerated peri- post-menopausal woman moderate risk development breast cancer .</brief_summary>
	<brief_title>Pilot Study Effect Duavee速 Benign Breast Tissue Proliferation</brief_title>
	<detailed_description>Duavee速 tissue specific estrogen complex bazedoxifene plus conjugated estrogen FDA approve relief menopausal symptom prevention osteoporosis woman uterus diagnosed estrogen dependent neoplasia . The overall purpose research demonstrate preliminary fashion despite reduction menopausal symptom , ( Duavee速 ) increase may decrease proliferation benign breast tissue cohort peri- post-menopausal woman moderately increase risk breast cancer . If pilot show rapid accrual , good retention , lack significant increase risk biomarker Ki-67 benign breast tissue , large prevention trial envision</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Women vasomotor symptom uterus postmenopausal late menopause transition Body Mass Index ( BMI ) &lt; 36 kg/m2 Class IIII mammogram within 6 month Random Periareolar Fine Needle Aspiration ( RPFNA ) ; If Class 0 4 , must resolve additional procedure If previously oral contraceptive hormone replacement , 8 week prior baseline RPFNA ; exception low dose vaginal hormone Confirmed moderate risk develop breast cancer RPFNA result within study define range Kidney liver function within study define range Willing able comply study related procedure Previous biopsy show evidence breast cancer Have predisposition prior history thromboembolism , deep venous thrombosis , pulmonary embolism , stroke History renal liver disease Prior ovarian endometrial cancer Stopped start hormone replacement within 8 week Any condition intercurrent illness opinion investigator make woman poor candidate RPFNA Currently take take specific medication past 6 month Participation chemoprevention trial within 6 month Current illness would make potential participant unsuitable enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>